The study conducted by Balcar et al. 49 examined the post-treatment immunoglobulin G (IgG) change in blood of 72 HCC patients treated with PD-1 ICI (such as nivolumab and pembrolizumab) or PD-L1 ICI (atezolizumab) combined with or without VEGF inhibitor (bevacizumab) and demonstrated that low IgG increase (< 14%) was correlated with longer median OS (15.9 vs. 6.4 months, P value = 0.001) and PFS (7.9 vs. 2.9 months, P value = 0.011) than high IgG increase (≥ 14%). This evidence concerns the gene VEGFA and hepatocellular carcinoma.